NeoGenesis Capital Fund I, LP
Raising: Form D filed Jul 2026 reports an open-ended (indefinite) offering
- Vintage
- 2026
- Fund size
- $33.08M (Form D)
- Stages
- Not stated
- Sectors
- Synthetic biology, Biotech, Agtech
- Regions
- Not stated
01 · Thesis
Invests in Colossal Biosciences and companies built on its programmable biology platform, where superintelligence meets synthetic biology. Finances the industrialization of biology, turning genetic code into living products, through a concentrated single-ecosystem strategy.Inferred from the firm's website
02 · Initial check
$331K to $551K (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Peter H. Diamandis, MD, Co-Founder and Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideThe firm invests in Colossal Biosciences and in the companies built on and gestated out of Colossal’s platform, where superintelligence meets synthetic biology. The fund is designed to invest in the programmable biology platform and in what it produces.
today announced its launch and the initial closing of its first fund.
https://neogenesiscapital.com/newsroom/neogenesis-capital-launches-fund/Firm-wideNeoGenesis Capital finances the industrialization of biology, turning genetic code into living products across markets measured in the trillions.
NeoGenesis Capital finances the industrialization of biology, turning genetic code into living products across markets measured in the trillions.
https://neogenesiscapital.com/
06 · Sources
Last verified: Oct 28, 2026